Amalgamated Bank Grows Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Amalgamated Bank increased its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 30.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,182 shares of the company’s stock after buying an additional 511 shares during the quarter. Amalgamated Bank’s holdings in Nurix Therapeutics were worth $49,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Nurix Therapeutics by 31.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company’s stock valued at $54,000 after buying an additional 559 shares in the last quarter. International Assets Investment Management LLC raised its stake in Nurix Therapeutics by 1,098.4% in the 3rd quarter. International Assets Investment Management LLC now owns 4,494 shares of the company’s stock valued at $101,000 after purchasing an additional 4,119 shares during the last quarter. GAMMA Investing LLC raised its position in shares of Nurix Therapeutics by 299.8% in the second quarter. GAMMA Investing LLC now owns 4,566 shares of the company’s stock valued at $95,000 after buying an additional 3,424 shares during the last quarter. EntryPoint Capital LLC purchased a new position in shares of Nurix Therapeutics during the 1st quarter worth $123,000. Finally, Dark Forest Capital Management LP acquired a new stake in shares of Nurix Therapeutics in the second quarter worth approximately $201,000.

Nurix Therapeutics Price Performance

Shares of Nurix Therapeutics stock opened at $21.79 on Tuesday. The business has a fifty day simple moving average of $24.51 and a two-hundred day simple moving average of $21.34. The company has a market capitalization of $1.54 billion, a price-to-earnings ratio of -7.49 and a beta of 2.20. Nurix Therapeutics, Inc. has a 1 year low of $5.65 and a 1 year high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings data on Friday, October 11th. The company reported ($0.67) earnings per share for the quarter, meeting the consensus estimate of ($0.67). The firm had revenue of $12.59 million during the quarter, compared to analysts’ expectations of $13.85 million. Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. As a group, equities analysts anticipate that Nurix Therapeutics, Inc. will post -2.81 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

NRIX has been the topic of several research reports. Royal Bank of Canada cut their price target on shares of Nurix Therapeutics from $27.00 to $26.00 and set an “outperform” rating on the stock in a report on Monday, October 14th. UBS Group began coverage on Nurix Therapeutics in a research note on Thursday, October 24th. They set a “buy” rating and a $35.00 price objective on the stock. Jefferies Financial Group assumed coverage on shares of Nurix Therapeutics in a report on Friday, October 11th. They issued a “buy” rating and a $41.00 target price on the stock. Stephens restated an “overweight” rating and issued a $31.00 target price on shares of Nurix Therapeutics in a research report on Monday, October 14th. Finally, Oppenheimer upped their price target on shares of Nurix Therapeutics from $27.00 to $30.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 4th. One investment analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $29.40.

Insider Activity

In other Nurix Therapeutics news, CFO Houte Hans Van sold 20,000 shares of the stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $25.22, for a total transaction of $504,400.00. Following the completion of the sale, the chief financial officer now owns 31,002 shares of the company’s stock, valued at approximately $781,870.44. This represents a 39.21 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Gwenn Hansen sold 3,437 shares of Nurix Therapeutics stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $24.30, for a total value of $83,519.10. Following the completion of the transaction, the insider now directly owns 50,670 shares of the company’s stock, valued at approximately $1,231,281. This trade represents a 6.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 57,321 shares of company stock worth $1,414,409. Insiders own 7.20% of the company’s stock.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.